Biogen: cross-border access for the specialty portfolio

Quick orientation

Biogen Inc. is a US-headquartered biotechnology company based in Cambridge, Massachusetts. Biogen's specialty footprint is anchored in spinal muscular atrophy (Spinraza), Alzheimer's disease via the Eisai partnership (Leqembi), Friedreich's ataxia (Skyclarys, acquired with Reata Pharmaceuticals in 2023), multiple sclerosis (Tysabri, Tecfidera, Vumerity, Plegridy, Avonex), and a small set of additional CNS and rare-disease products. The MS franchise is mature but the SMA, Alzheimer's, and Friedreich's ataxia franchises are the active cross-border drivers.

Portfolio in cross-border NPP scope

Spinraza (nusinersen)

Antisense oligonucleotide approved for spinal muscular atrophy across pediatric and adult patients. Administered as intrathecal injection on a loading-then-maintenance schedule. US WAC at the maintenance schedule runs at approximately $625,000 in year one and $375,000 per year thereafter. Cross-border requests come from SMA patients in MENA and India where local Spinraza supply is intermittent, where the adult SMA indication is locally narrow, or where the family has chosen Spinraza over the oral Evrysdi or the gene-therapy Zolgensma alternatives.

Leqembi (lecanemab, co-marketed with Eisai)

Anti-amyloid monoclonal antibody approved for early symptomatic Alzheimer's disease with confirmed amyloid pathology. Cross-border requests come from early symptomatic AD patients in the Gulf and India where amyloid PET or CSF biomarker confirmation has been obtained but the anti-amyloid pathway is not yet locally registered. Reserve Meds coordinates Leqembi with attention to the required MRI monitoring schedule for ARIA.

Skyclarys (omaveloxolone)

Nrf2 activator approved for Friedreich's ataxia in patients 16 and older. International requests come from Friedreich's ataxia patients in MENA and India where the disease prevalence is recognized but no on-label disease-modifying therapy has been locally registered.

Qalsody (tofersen)

Antisense oligonucleotide for amyotrophic lateral sclerosis associated with mutations in the SOD1 gene. International requests are by definition very small but high-acuity: SOD1-mutated ALS is rare, and Qalsody is the first targeted therapy for this subgroup.

Tysabri (natalizumab)

Anti-alpha-4-integrin monoclonal antibody for relapsing MS and Crohn's disease, with restricted-distribution REMS in the US for PML monitoring. International requests come from MS patients in MENA and India who have failed other DMTs and need a high-efficacy option, where the JC-virus screening protocol has been established locally.

Vumerity (diroximel fumarate) and Tecfidera (dimethyl fumarate)

Oral fumarate MS therapies. Vumerity is the newer formulation with improved GI tolerability. International requests cluster around MS patients who have failed dimethyl fumarate due to GI intolerance.

Plegridy and Avonex (peginterferon beta-1a and interferon beta-1a)

Interferon-based MS therapies. Demand is declining as oral and high-efficacy biologics have moved upstream, but specific patients on long-term Plegridy continuity of care route through Reserve Meds when local supply is intermittent.

Why patients route Biogen products through cross-border NPP

Three patterns dominate. First, SMA in adults: the Spinraza adult indication is locally narrow in many MENA and India markets. Second, Leqembi and the early Alzheimer's anti-amyloid pathway is largely US-only in 2026. Third, Skyclarys for Friedreich's ataxia and Qalsody for SOD1-ALS are tertiary-rare populations where local registration has not happened. The Biogen Patient Services program is restricted to US residents.

Manufacturer engagement posture

Reserve Meds coordinates Biogen-manufactured US product through DSCSA-compliant specialty wholesaler channels. We are not an authorized Biogen distributor. All Reserve Meds orders are cash-pay at firm-quote pricing.

For Biogen and Eisai-co-marketed market access teams: Reserve Meds maintains structured demand visibility across SMA, Alzheimer's, Friedreich's ataxia, ALS, and MS franchises. If your group is sizing pre-registration demand in MENA and India, we are open to a structured conversation under NDA.

Common cross-border destinations for the Biogen portfolio

Spinraza concentrates in pediatric neurology centers in India, Egypt, Saudi Arabia, and the UAE. Leqembi is heaviest in the Gulf where private neurology imaging infrastructure supports the amyloid PET and MRI-monitoring requirements. Skyclarys and Qalsody serve tertiary specialty centers in the UAE, India, and Egypt. The MS franchise tracks established MS centers across the region.

What Reserve Meds provides

For every Biogen product order, Reserve Meds coordinates DSCSA chain-of-custody documentation; cold-chain validated logistics where required; country regulatory pathway expertise covering named-patient import approval, customs clearance, and any required physician declaration; and a single patient-facing coordinator. We do not replace the patient's treating physician. A US-licensed pharmacist reviews every prescription before dispensing.

Next step for patients

Patients or caregivers who have a treating physician's prescription for a Biogen product and want a firm quote can start a request below.

Start a request for a Biogen product

Next step for Biogen teams

If you are on the Biogen access, medical affairs, or international market access team and want to discuss coordinated named-patient program demand from MENA and India, reach us at [email protected]. We will share aggregated demand views under NDA.

Reserved for you.